Clinical trials
Phase 2 Neurotoxicity Syndromes trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 2 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Terminated | 4 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 2 |
| University of South Florida | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| City of Hope Medical Center | 1 |
| Columbia University | 1 |
| Fudan University | 1 |
| Fundacion Oncosur | 1 |
| Gerald Higa, PharmD. | 1 |
| Gynecologic Oncology Group | 1 |
| Institut Cancerologie de l'Ouest | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neurotoxicity Syndromes | 20 |
| Peripheral Nervous System Diseases | 4 |
| Carcinoma, Ovarian Epithelial | 3 |
| Lymphoma | 3 |
| Ovarian Neoplasms | 3 |
| Breast Neoplasms | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Lung Neoplasms | 2 |
| Sarcoma | 2 |
| Burkitt Lymphoma | 1 |
Trials
Showing 51 to 20 of 20. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.